ZA200101157B - Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody. - Google Patents

Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody. Download PDF

Info

Publication number: ZA200101157B
Authority: ZA; South Africa
Prior art keywords: nhl; antibody; substance; composition; lymphoma
Prior art date: 1998-08-11

Application number

ZA200101157A

Other languages

English (en)

Inventor

Antonio Grillo-Lopez

Original Assignee

Idec Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-11

Filing date

2001-02-09

Publication date

2002-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200101157(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-02-09 Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp

2002-07-10 Publication of ZA200101157B publication Critical patent/ZA200101157B/en

Links

208000003950 B-cell lymphoma Diseases 0.000 title claims description 48
238000002648 combination therapy Methods 0.000 title description 5
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 144
238000011282 treatment Methods 0.000 claims description 81
229960004641 rituximab Drugs 0.000 claims description 71
238000000034 method Methods 0.000 claims description 54
239000000203 mixture Substances 0.000 claims description 46
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 36
210000004027 cell Anatomy 0.000 claims description 33
206010028980 Neoplasm Diseases 0.000 claims description 30
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 28
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 28
230000003325 follicular Effects 0.000 claims description 27
238000002560 therapeutic procedure Methods 0.000 claims description 27
238000002512 chemotherapy Methods 0.000 claims description 25
201000010099 disease Diseases 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
230000001225 therapeutic effect Effects 0.000 claims description 23
102000004127 Cytokines Human genes 0.000 claims description 18
108090000695 Cytokines Proteins 0.000 claims description 18
210000004881 tumor cell Anatomy 0.000 claims description 17
208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 12
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 12
208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 12
GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims description 12
230000003442 weekly effect Effects 0.000 claims description 12
208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 11
108010047761 Interferon-alpha Proteins 0.000 claims description 11
102000006992 Interferon-alpha Human genes 0.000 claims description 11
206010025312 Lymphoma AIDS related Diseases 0.000 claims description 11
201000003444 follicular lymphoma Diseases 0.000 claims description 11
230000000527 lymphocytic effect Effects 0.000 claims description 11
210000000130 stem cell Anatomy 0.000 claims description 11
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 9
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
210000002798 bone marrow cell Anatomy 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
238000001959 radiotherapy Methods 0.000 claims description 7
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 6
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 6
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
230000000973 chemotherapeutic effect Effects 0.000 claims description 6
229960000684 cytarabine Drugs 0.000 claims description 6
229960000908 idarubicin Drugs 0.000 claims description 6
NYNAFINLHQEHKU-UHFFFAOYSA-N methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(=O)C(C=C1)=CC=C1NCC1=CN=C(N=C(N)N=C2N)C2=N1 NYNAFINLHQEHKU-UHFFFAOYSA-N 0.000 claims description 6
229960001156 mitoxantrone Drugs 0.000 claims description 6
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 6
230000001400 myeloablative effect Effects 0.000 claims description 6
KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 claims description 6
102000008070 Interferon-gamma Human genes 0.000 claims description 5
108010074328 Interferon-gamma Proteins 0.000 claims description 5
108010002350 Interleukin-2 Proteins 0.000 claims description 5
102000000588 Interleukin-2 Human genes 0.000 claims description 5
238000010322 bone marrow transplantation Methods 0.000 claims description 5
229940044627 gamma-interferon Drugs 0.000 claims description 5
238000011476 stem cell transplantation Methods 0.000 claims description 5
230000002195 synergetic effect Effects 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
238000009104 chemotherapy regimen Methods 0.000 claims description 4
230000000996 additive effect Effects 0.000 claims description 3
239000000126 substance Substances 0.000 claims 45
230000004044 response Effects 0.000 description 24
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 23
206010025323 Lymphomas Diseases 0.000 description 21
210000003719 b-lymphocyte Anatomy 0.000 description 18
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 16
241001529936 Murinae Species 0.000 description 12
239000000427 antigen Substances 0.000 description 12
108091007433 antigens Proteins 0.000 description 12
102000036639 antigens Human genes 0.000 description 12
238000001802 infusion Methods 0.000 description 12
238000011285 therapeutic regimen Methods 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
230000009286 beneficial effect Effects 0.000 description 7
239000002738 chelating agent Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 6
210000001185 bone marrow Anatomy 0.000 description 6
229960000390 fludarabine Drugs 0.000 description 6
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 6
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
230000001588 bifunctional effect Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229960004397 cyclophosphamide Drugs 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000003827 upregulation Effects 0.000 description 5
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 3
208000007660 Residual Neoplasm Diseases 0.000 description 3
238000009175 antibody therapy Methods 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229960004630 chlorambucil Drugs 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229910052738 indium Inorganic materials 0.000 description 3
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 3
238000011221 initial treatment Methods 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000011268 retreatment Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940045799 anthracyclines and related substance Drugs 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000008279 sol Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
230000005909 tumor killing Effects 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
-1 1-methyl-3-isothiocyanatobenzyl- Chemical group 0.000 description 1
208000012526 B-cell neoplasm Diseases 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
206010025280 Lymphocytosis Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010033661 Pancytopenia Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
238000001994 activation Methods 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
210000003040 circulating cell Anatomy 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
208000024389 cytopenia Diseases 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229940063725 leukeran Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
208000021937 marginal zone lymphoma Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
206010029410 night sweats Diseases 0.000 description 1
230000036565 night sweats Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000009877 rendering Methods 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960005267 tositumomab Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000009466 transformation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/001—Processes for the treatment of water whereby the filtration technique is of importance
- C02F1/003—Processes for the treatment of water whereby the filtration technique is of importance using household-type filters for producing potable water, e.g. pitchers, bottles, faucet mounted devices
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2307/00—Location of water treatment or water treatment device
- C02F2307/02—Location of water treatment or water treatment device as part of a bottle
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Hydrology & Water Resources (AREA)
Environmental & Geological Engineering (AREA)
Water Supply & Treatment (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200101157A 1998-08-11 2001-02-09 Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody. ZA200101157B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9618098P	1998-08-11	1998-08-11

Publications (1)

Publication Number	Publication Date
ZA200101157B true ZA200101157B (en)	2002-07-10

Family

ID=22256115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200101157A ZA200101157B (en)	1998-08-11	2001-02-09	Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody.

Country Status (27)

Country	Link
US (13)	US6455043B1 (fr)
EP (7)	EP2260866A1 (fr)
JP (9)	JP2002522511A (fr)
KR (5)	KR101063278B1 (fr)
CN (5)	CN1320044A (fr)
AT (1)	ATE414536T1 (fr)
AU (3)	AU767965C (fr)
BR (1)	BR9913645A (fr)
CA (1)	CA2340091C (fr)
CY (2)	CY1108906T1 (fr)
CZ (1)	CZ303898B6 (fr)
DE (1)	DE69939939D1 (fr)
DK (2)	DK1974747T3 (fr)
EA (1)	EA004107B1 (fr)
ES (2)	ES2388893T3 (fr)
HK (1)	HK1041221A1 (fr)
HU (1)	HU228180B1 (fr)
IL (4)	IL141349A0 (fr)
MX (1)	MXPA01001530A (fr)
MY (1)	MY136203A (fr)
NO (2)	NO332893B3 (fr)
NZ (2)	NZ573838A (fr)
PL (1)	PL195870B1 (fr)
PT (2)	PT1974747E (fr)
TW (4)	TWI355941B (fr)
WO (1)	WO2000009160A1 (fr)
ZA (1)	ZA200101157B (fr)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
PT752248E (pt) *	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
WO2001060397A1 (fr) *	2000-02-16	2001-08-23	Genentech, Inc.	Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
DE69939939D1 (de)	1998-08-11	2009-01-02	Idec Pharma Corp	Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
ES2351149T3 (es)	1998-11-09	2011-02-01	Biogen Idec Inc.	Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
TR200101302T2 (tr) *	1998-11-09	2001-10-22	Idec Pharmaceuticals Corporation	BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
WO2000061739A1 (fr)	1999-04-09	2000-10-19	Kyowa Hakko Kogyo Co., Ltd.	Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
IL146005A0 (en)	1999-05-07	2002-07-25	Genentech Inc	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
KR20020027490A (ko) *	1999-07-12	2002-04-13	제넨테크, 인크.	Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
US6451284B1 (en) *	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
JP2003513012A (ja) *	1999-08-11	2003-04-08	アイデックファーマスーティカルズコーポレイション	抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
EP2264070A1 (fr) *	1999-08-11	2010-12-22	Biogen-Idec Inc.	Traitement du lymphome non Hodgkin à haute teneur et intermédiaire avec anticorps anti-CD20
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2005211669C1 (en) *	1999-08-11	2017-09-21	F. Hoffmann-La Roche Ag	Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
WO2001072333A1 (fr) *	2000-03-24	2001-10-04	Chiron Corporation	Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20
CN1981868A (zh) *	2000-03-31	2007-06-20	拜奥根Idec公司	抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CA2405632A1 (fr) *	2000-04-25	2001-11-01	Idec Pharmaceutical Corporation	Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
JP2004512262A (ja)	2000-06-20	2004-04-22	アイデック　ファーマスーティカルズ　コーポレイション	非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
DE60139689D1 (de) *	2000-06-22	2009-10-08	Univ Iowa Res Found	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
KR20040023565A (ko) *	2000-09-18	2004-03-18	아이덱 파마슈티칼즈 코포레이션	Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
KR20030091978A (ko) *	2001-01-29	2003-12-03	아이덱 파마슈티칼즈 코포레이션	변형된 항체 및 사용 방법
EP2359849A1 (fr) *	2001-04-02	2011-08-24	Genentech, Inc.	Polytherapie
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1404366A4 (fr) *	2001-06-14	2006-06-07	Intermune Inc	Therapie combinee faisant appel a l'interferon gamma et a des anticorps specifiques des cellules b
PL377119A1 (pl) *	2001-08-03	2006-01-23	Genentech, Inc.	Peptydy TACIs i BR3 i ich zastosowanie
AU2002326581A1 (en) *	2001-08-10	2003-03-03	University Of Virginia Patent Foundation	Enhancing the efficacy of immunotherapies by supplementing with complement
US20040093621A1 (en) *	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
JP2005526501A (ja)	2002-02-21	2005-09-08	デューク・ユニヴァーシティ	自己免疫疾患用の試薬および治療方法
WO2003084569A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Medicament contenant une composition anticorps
AU2003243415A1 (en) *	2002-06-07	2003-12-22	Zymogenetics, Inc.	Use of il-21 in cancer and other therapeutic applications
WO2004011611A2 (fr) *	2002-07-25	2004-02-05	Genentech, Inc.	Anticorps anti-taci et utilisations de ceux-ci
US20050180972A1 (en) *	2002-07-31	2005-08-18	Wahl Alan F.	Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
PT1558648E (pt) *	2002-10-17	2012-04-23	Genmab As	Anticorpos monoclonais humanos contra cd20
SE0203731D0 (sv) *	2002-12-13	2002-12-13	Mitra Medical Technology Ab	Reagent
WO2004054615A1 (fr) *	2002-12-13	2004-07-01	Mitra Medical Technology Ab	Agents de traitement anti-lymphome possedant des fonctions d'effecteur et d'affinite liees au moyen d'un reactif trifonctionnel
CN1751236A (zh) *	2002-12-16	2006-03-22	健泰科生物技术公司	表达人cd20的转基因小鼠
AR042485A1 (es) *	2002-12-16	2005-06-22	Genentech Inc	Anticuerpo humanizado que se une al cd20 humano
MXPA05010778A (es) *	2003-04-09	2005-12-12	Genentech Inc	Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
KR101412271B1 (ko) *	2003-05-09	2014-06-25	듀크 유니버시티	Ｃｄ２０-특이적 항체 및 이를 이용한 방법
AR044388A1 (es) *	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
NZ543712A (en) *	2003-06-05	2008-06-30	Genentech Inc	Combination therapy for B cell disorders
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
US20040254108A1 (en) *	2003-06-13	2004-12-16	Jing Ma	Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) *	2003-06-13	2005-10-20	Oncomax Acquisition Corp.	Preparation and application of anti-tumor bifunctional fusion proteins
US20060240005A1 (en) *	2003-07-24	2006-10-26	Universita Degli Studi Di Perugia	Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US7803376B2 (en) *	2003-07-24	2010-09-28	Innate Pharma S.A.	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005017529A1 (fr) *	2003-07-29	2005-02-24	Genentech, Inc.	Dosage pour anticorps humains contre cd20 et leurs utilisations
JP2007504138A (ja) *	2003-08-29	2007-03-01	ジェネンテック・インコーポレーテッド	眼疾患の治療法
CA2539432A1 (fr) *	2003-09-23	2005-04-07	Favrille, Inc.	Modification d'une pathologie de lymphocytes b au moyen d'antigenes autoderives en conjugaison avec un agent cytoreducteur a liaison specifique
EP2633866A3 (fr) *	2003-10-17	2013-12-18	Novo Nordisk A/S	Thérapie combinée
GB0324368D0 (en) *	2003-10-17	2003-11-19	Univ Cambridge Tech	Polypeptides including modified constant regions
WO2005044307A2 (fr)	2003-11-04	2005-05-19	Chiron Corporation	Procedes de therapie pour des cancers lies a la cellule b
TR201809892T4 (tr)	2003-11-05	2018-07-23	Roche Glycart Ag	Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
AU2004303848A1 (en) *	2003-12-19	2005-07-07	Genentech, Inc.	Detection of CD20 in transplant rejection
EP1696955A2 (fr) *	2003-12-19	2006-09-06	Genentech, Inc.	Detection cd20 pour traitement des maladies auto-immunes
EP1709196A4 (fr) *	2003-12-22	2008-10-29	Novartis Vaccines & Diagnostic	Utilisation des polymorphismes du recepteur fc comme diagnostic pour des strategies de traitement des troubles de la reponse immunitaire
AU2005244751A1 (en) *	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting B cell depletion
EP1742660A2 (fr) *	2004-04-16	2007-01-17	Genentech, Inc.	Traitement de troubles
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
CN1980697A (zh) *	2004-05-05	2007-06-13	健泰科生物技术公司	通过使用抗cd20抗体预防自身免疫病
EP2425847A1 (fr)	2004-05-20	2012-03-07	ZymoGenetics, Inc.	Procédés pour traiter le cancer au moyen d'IL-21 et une thérapie par anticorps monoclonaux
AR049292A1 (es) *	2004-06-04	2006-07-12	Genentech Inc	Metodo para tratar lupus con un anticuerpo cd20
AU2005249566B2 (en)	2004-06-04	2010-11-11	Genentech, Inc.	Method for treating multiple sclerosis
JP2008505148A (ja) *	2004-07-09	2008-02-21	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療
EP1781378A2 (fr) *	2004-07-22	2007-05-09	Genentech, Inc.	Procede pour traiter le syndrome de sjögren
DK2213683T3 (da)	2004-08-04	2013-09-02	Mentrik Biotech Llc	VARIANT-Fc-REGIONER
ZA200702335B (en) *	2004-10-05	2009-05-27	Genentech Inc	Method for treating vasculitis
GB2420976B (en) *	2004-11-19	2006-12-20	Zvi Finkelstein	Therapeutic implant
US20060188495A1 (en) *	2005-01-13	2006-08-24	Genentech, Inc.	Treatment method
CN102580084B (zh)	2005-01-21	2016-11-23	健泰科生物技术公司	Her抗体的固定剂量给药
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2006089064A1 (fr) *	2005-02-15	2006-08-24	Novartis Vaccines And Diagnostics Inc.	Méthodes de traitement de lymphomes utilisant une combinaison comprenant un agent chimiothérapeutique, une il-2 et éventuellement un anticorps anti-cd20
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
EA037929B1 (ru) *	2005-03-23	2021-06-08	Генмаб А/С	Антитела к cd38 человека и их применение
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
WO2006111524A2 (fr) *	2005-04-18	2006-10-26	Novo Nordisk A/S	Variantes de l'il-21
KR20070122497A (ko) *	2005-04-22	2007-12-31	제넨테크, 인크.	Ｃｄ20 항체로 치매 또는 알츠하이머병을 치료하는 방법
CN101223448B (zh)	2005-05-20	2012-01-18	健泰科生物技术公司	来自自身免疫病受试者的生物学样品的预处理
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
PT1912675E (pt)	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
US20080213273A1 (en)	2005-07-25	2008-09-04	Trubion Pharmaceuticals Inc.	Single dose use of CD20-specific binding molecules
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
US20070136826A1 (en) *	2005-12-02	2007-06-14	Biogen Idec Inc.	Anti-mouse CD20 antibodies and uses thereof
US20070134249A1 (en) *	2005-12-08	2007-06-14	Genitope Corporation	Combination therapy and antibody panels
EP2639242A3 (fr)	2006-03-06	2013-10-16	MedImmune, Inc.	Anticorps humanisés dirigés contre l'antigène CD22 et leur utilisation dans le traitement de l'oncologie, des transplantations et les maladies auto-immunes
EP2540741A1 (fr)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Anticorps humanisés anti CD22 et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
MX380352B (es)	2006-06-12	2025-03-12	Aptevo Res & Development Llc	Proteinas de union multivalentes monocatenarias con funcion efectora.
ME03503B (fr) *	2006-09-26	2020-04-20	Genmab As	Traitement combiné de tumeurs exprimant la cd38
CA2666426A1 (fr)	2006-10-26	2008-05-02	Novo Nordisk A/S	Variantes il-21
WO2008074863A1 (fr) *	2006-12-21	2008-06-26	Novo Nordisk A/S	Variants de l'interleukine-21 avec une liaison modifiée au récepteur de il-21
US8280711B2 (en) *	2007-03-12	2012-10-02	ESBATech, an Alcon Biomedical Research Unit, LLC.	Sequence based engineering and optimization of single chain antibodies
CN101687036A (zh) *	2007-04-27	2010-03-31	阿斯利康(瑞典)有限公司	治疗恶性血液病的chk1抑制剂与b细胞耗尽抗体
PT2170956E (pt)	2007-06-15	2015-02-05	Medigene Ag	Tratamento de tumores utilizando um anticorpo anti-l1 específico
DK2164961T3 (en) *	2007-06-25	2015-03-02	Esbatech Alcon Biomed Res Unit	Sequence based forward position and optimization of single chain antibodies
WO2009000099A2 (fr) *	2007-06-25	2008-12-31	Esbatech Ag	Méthodes de modification d'anticorps et anticorps modifiés présentant des propriétés fonctionnelles améliorées
HUE046992T2 (hu)	2007-07-09	2020-04-28	Genentech Inc	Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP2178916B1 (fr) *	2007-07-31	2014-12-17	Regeneron Pharmaceuticals, Inc.	Anticorps humains contre le cd20 humain et leur procede d'utilisation
EP2200631A1 (fr)	2007-10-16	2010-06-30	Zymogenetics, Inc.	Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
AU2008342956A1 (en) *	2007-12-21	2009-07-09	Genentech, Inc.	Therapy of rituximab-refractory rheumatoid arthritis patients
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (fr)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
RS51975B (sr)	2008-04-11	2012-02-29	Emergent Product Development Seattle Llc.	Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
PT3241843T (pt)	2008-06-25	2021-09-10	Novartis Ag	Otimização da solubilidade de imunoligantes
TW201438738A (zh)	2008-09-16	2014-10-16	Genentech Inc	治療進展型多發性硬化症之方法
WO2010075249A2 (fr)	2008-12-22	2010-07-01	Genentech, Inc.	Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
SI2464725T2 (sl)	2009-08-11	2025-06-30	F. Hoffmann-La Roche Ag	Proizvodnja beljakovin v medijih za celične kulture brez glutamina
RU2421217C2 (ru) *	2009-09-03	2011-06-20	Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН)	Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2533810B1 (fr)	2010-02-10	2016-10-12	ImmunoGen, Inc.	Anticorps anti-cd20 et utilisations de ceux-ci
DE102010015276A1 (de)	2010-04-15	2011-10-20	A. Eberle Gmbh & Co. Kg	Steuerung/Regelung der Sekundärspannung von Ortsnetztransformatoren durch den Einsatz von netzgeführten Wechselrichtern
SI2580243T1 (sl)	2010-06-09	2020-02-28	Genmab A/S	Protitelesa proti humanemu CD38
RU2013106216A (ru) *	2010-08-03	2014-09-10	Ф. Хоффманн-Ля Рош Аг	Биомаркеры хронической лимфоцитарной лейкемии
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RS63430B1 (sr)	2010-10-01	2022-08-31	Modernatx Inc	Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
WO2012096975A2 (fr) *	2011-01-13	2012-07-19	The Board Of Trustees Of The Leland Stanford Junior University	Méthode de prédiction de la réactivité de tumeurs malignes d'une lignée de lymphocytes b à une immunothérapie active
EP2691101A2 (fr)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Administration et formulation d'acides nucléiques génétiquement modifiés
EP3626739A1 (fr)	2011-06-24	2020-03-25	Stephen D. Gillies	Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
KR102117202B1 (ko) *	2011-08-16	2020-06-01	모르포시스 아게	항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US20140234307A1 (en)	2011-09-27	2014-08-21	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
DK3682905T3 (da)	2011-10-03	2022-02-28	Modernatx Inc	Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
BR112014010008A2 (pt)	2011-10-26	2018-09-04	Novartis Ag	anticorpos monoclonais, seus usos e ácidos nucleicos
DE12858350T1 (de)	2011-12-16	2021-10-07	Modernatx, Inc.	Modifizierte mrna zusammensetzungen
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en)	2012-04-02	2016-01-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
RU2550663C2 (ru) *	2013-02-13	2015-05-10	Владимир Владимирович Савостьянов	Способ гормонально-лучевой подготовки больных хроническим лимфолейкозом к последующей химиотерапии
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
ES2741643T3 (es) *	2013-06-07	2020-02-11	Nordic Nanovector Asa	Terapia de combinación que comprende un anticuerpo anti-CD20 y el anticuerpo monoclonal HH1 radiomarcado
WO2015048744A2 (fr)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
WO2015051214A1 (fr)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
PE20210107A1 (es)	2013-12-17	2021-01-19	Genentech Inc	Anticuerpos anti-cd3 y metodos de uso
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
BR112017001860A2 (pt)	2014-07-31	2018-02-27	Uab Research Foundation	peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
US9751946B2 (en)	2014-09-12	2017-09-05	Genentech, Inc.	Anti-CLL-1 antibodies and immunoconjugates
PT3221359T (pt)	2014-11-17	2020-06-23	Regeneron Pharma	Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
CN107108718B (zh) *	2014-12-08	2022-07-22	北京强新生物科技有限公司	可溶性通用的增强adcc的合成融合基因和融合肽的技术及其应用
EP3271485A4 (fr) *	2015-03-18	2019-01-16	Memorial Sloan-Kettering Cancer Center	Procédés permettant de diagnostiquer et de traiter le lymphome folliculaire
LT3303373T (lt)	2015-05-30	2020-07-10	Molecular Templates, Inc.	Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
EP3310378B1 (fr)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anticorps anti-c1 et leurs procédés d'utilisation
CN107849132B (zh)	2015-06-16	2022-03-08	豪夫迈·罗氏有限公司	人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
UA123053C2 (uk)	2015-06-24	2021-02-10	Ф. Хоффманн-Ля Рош Аг	Антитіло до рецептора трансферину зі спеціально підібраною афінністю
BR112018005573A2 (pt)	2015-09-21	2019-01-22	Aptevo Research And Development Llc	?polipeptídeos de ligação a cd3?
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
HRP20210938T1 (hr) *	2016-05-30	2021-09-03	Morphosys Ag	Postupci za prognozu terapijske dobrobiti od anti-cd19 terapije kod pacijenata
US20190330318A1 (en)	2016-07-25	2019-10-31	Biogen Ma Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
CN108421048B (zh) *	2016-09-28	2021-04-20	首都医科大学附属北京世纪坛医院	纳米活性碳靶向药物递送系统、制备方法及其用途
CN109923128A (zh)	2016-11-15	2019-06-21	基因泰克公司	用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
US10610104B2 (en)	2016-12-07	2020-04-07	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
US10350266B2 (en) *	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en)	2017-01-10	2020-03-31	Nodus Therapeutics	Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
GB201703876D0 (en) *	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
EP3600416B1 (fr)	2017-03-30	2023-06-07	Biora Therapeutics, Inc.	Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
CN118772288A (zh)	2018-02-08	2024-10-15	豪夫迈·罗氏有限公司	双特异性抗原结合分子和使用方法
WO2019213589A1 (fr) *	2018-05-04	2019-11-07	Portola Pharmaceuticals, Inc.	Méthodes de traitement de lymphomes
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3820475A4 (fr)	2018-07-09	2022-04-13	Takeda Pharmaceutical Company Limited	Administration d'inhibiteur d'enzyme d'activation sumo et anticorps anti-cd20
IL280875B2 (en)	2018-08-31	2024-12-01	Regeneron Pharma	Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
WO2020106757A1 (fr)	2018-11-19	2020-05-28	Progenity, Inc.	Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
AU2019389807B2 (en) *	2018-11-30	2025-01-23	Fondazione Centro San Raffaele	Combined treatment of primary central nervous system lymphoma
JP2022529536A (ja) *	2019-04-25	2022-06-22	アクティニウムファーマシューティカルズインコーポレイテッド	悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
KR20220113790A (ko)	2019-12-13	2022-08-16	제넨테크, 인크.	항-ly6g6d 항체 및 사용 방법
EP3967307A1 (fr)	2020-09-15	2022-03-16	Instytut Hematologii I Transfuzologii	Utilisation d'inhibiteurs de la pim kinase pour augmenter l'efficacité des thérapies anti-cd20 à base d'anticorps dans les malignités hématologiques et les affections non malignes
MX2023005130A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
WO2022098638A2 (fr)	2020-11-04	2022-05-12	Genentech, Inc.	Dosage pour le traitement avec des anticorps bispécifiques anti-cd20/anti-cd3
KR20240007171A (ko)	2021-05-14	2024-01-16	제넨테크, 인크.	모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (fr)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
IL76591A0 (en) *	1984-10-05	1986-02-28	Bioferon Biochem Substanz	Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
EP0247091B1 (fr)	1985-11-01	1993-09-29	Xoma Corporation	Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5099069A (en)	1986-09-05	1992-03-24	Gansow Otto A	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en)	1986-09-05	1993-09-21	The United States Of America As Represented By The Secretary Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (fr)	1987-07-24	2001-05-22	Randy R. Robinson	Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5691320A (en) *	1987-10-28	1997-11-25	Pro-Neuron, Inc.	Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
JP3040121B2 (ja) *	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
US5225535A (en) *	1988-12-15	1993-07-06	The Wistar Institute	Lymphokine SAF and method of making
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5460785A (en)	1989-08-09	1995-10-24	Rhomed Incorporated	Direct labeling of antibodies and other protein with metal ions
SE8903003D0 (sv)	1989-09-12	1989-09-12	Astra Ab	Novel medical use
US5124471A (en)	1990-03-26	1992-06-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Bifunctional dtpa-type ligand
US5165922A (en)	1990-05-22	1992-11-24	Bristol-Myers Squibb Company	Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0556285A4 (en)	1990-11-05	1993-10-27	Bristol-Myers Squibb Company	Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
JP3105629B2 (ja)	1991-04-23	2000-11-06	サングスタットメディカルコーポレイション	特異的結合ペアのメンバーの細胞活性調節接合体
US5250732A (en) *	1991-07-18	1993-10-05	Genentech, Inc.	Ketamine analogues for treatment of thrombocytopenia
EP0605442B1 (fr)	1991-07-25	2003-04-16	Idec Pharmaceuticals Corporation	Anticorps de recombinaison pour therapie humaine
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ZA93391B (en) *	1992-01-21	1993-10-06	Tamrock World Corp	Battery changer on a mobile machine
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US6099846A (en)	1992-10-14	2000-08-08	The Board Of Trustees Of The Leland Stanford Junior University	Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5451518A (en)	1992-11-13	1995-09-19	Sloan-Kettering Institute For Cancer Research	Purified human ceramide-activated protein kinase
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5691135A (en) *	1993-01-26	1997-11-25	The Regents Of The University Of California	Immunoglobulin superantigen binding to gp 120 from HIV
US5801005A (en) *	1993-03-17	1998-09-01	University Of Washington	Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US6111166A (en) *	1994-09-19	2000-08-29	Medarex, Incorporated	Transgenic mice expressing human Fcα and β receptors
GB9425060D0 (en)	1994-12-13	1995-02-08	Univ Birmingham	Carcinoma treatment
US5716791A (en)	1996-05-09	1998-02-10	Meridian Diagnostics, Inc.	Immunoassay for H. pylori in fecal specimens
US6183744B1 (en)	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69939939D1 (de)	1998-08-11	2009-01-02	Idec Pharma Corp	Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
AU6047099A (en) *	1998-09-24	2000-04-10	Boston Medical Center Corporation	Compositions and methods for the treatment of chronic lymphocytic leukemia
TR200101302T2 (tr) *	1998-11-09	2001-10-22	Idec Pharmaceuticals Corporation	BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
ES2351149T3 (es)	1998-11-09	2011-02-01	Biogen Idec Inc.	Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CA2405632A1 (fr) *	2000-04-25	2001-11-01	Idec Pharmaceutical Corporation	Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
PT1558648E (pt) *	2002-10-17	2012-04-23	Genmab As	Anticorpos monoclonais humanos contra cd20
AR042485A1 (es)	2002-12-16	2005-06-22	Genentech Inc	Anticuerpo humanizado que se une al cd20 humano

1999
- 1999-08-11 DE DE69939939T patent/DE69939939D1/de not_active Expired - Lifetime
- 1999-08-11 CZ CZ20010526A patent/CZ303898B6/cs not_active IP Right Cessation
- 1999-08-11 AU AU55531/99A patent/AU767965C/en not_active Expired
- 1999-08-11 DK DK08005921.5T patent/DK1974747T3/da active
- 1999-08-11 KR KR1020097021865A patent/KR101063278B1/ko not_active Ceased
- 1999-08-11 NZ NZ573838A patent/NZ573838A/en not_active IP Right Cessation
- 1999-08-11 EP EP10009420A patent/EP2260866A1/fr not_active Withdrawn
- 1999-08-11 NZ NZ528199A patent/NZ528199A/en not_active IP Right Cessation
- 1999-08-11 JP JP2000564662A patent/JP2002522511A/ja active Pending
- 1999-08-11 PT PT08005921T patent/PT1974747E/pt unknown
- 1999-08-11 CN CN99811514A patent/CN1320044A/zh active Pending
- 1999-08-11 EA EA200100224A patent/EA004107B1/ru not_active IP Right Cessation
- 1999-08-11 EP EP10009422A patent/EP2263693A1/fr not_active Withdrawn
- 1999-08-11 CA CA2340091A patent/CA2340091C/fr not_active Expired - Lifetime
- 1999-08-11 HK HK02103000.0A patent/HK1041221A1/zh unknown
- 1999-08-11 EP EP15150112.9A patent/EP2990054A1/fr not_active Ceased
- 1999-08-11 DK DK99942074.8T patent/DK1112084T4/da active
- 1999-08-11 KR KR1020117003784A patent/KR101155957B1/ko not_active Ceased
- 1999-08-11 HU HU0103484A patent/HU228180B1/hu not_active IP Right Cessation
- 1999-08-11 CN CNB2005100626868A patent/CN100531798C/zh not_active Ceased
- 1999-08-11 KR KR1020017001749A patent/KR20010072388A/ko not_active Ceased
- 1999-08-11 EP EP10009419A patent/EP2275136A1/fr not_active Withdrawn
- 1999-08-11 US US09/372,202 patent/US6455043B1/en not_active Expired - Lifetime
- 1999-08-11 EP EP08005921A patent/EP1974747B1/fr not_active Revoked
- 1999-08-11 ES ES08005921T patent/ES2388893T3/es not_active Expired - Lifetime
- 1999-08-11 WO PCT/US1999/018120 patent/WO2000009160A1/fr not_active Ceased
- 1999-08-11 BR BR9913645-7A patent/BR9913645A/pt not_active Application Discontinuation
- 1999-08-11 MY MYPI99003434A patent/MY136203A/en unknown
- 1999-08-11 ES ES99942074T patent/ES2317702T5/es not_active Expired - Lifetime
- 1999-08-11 CN CNA2005100626887A patent/CN1689646A/zh active Pending
- 1999-08-11 EP EP99942074A patent/EP1112084B2/fr not_active Expired - Lifetime
- 1999-08-11 KR KR1020087008471A patent/KR20080038453A/ko not_active Ceased
- 1999-08-11 PT PT99942074T patent/PT1112084E/pt unknown
- 1999-08-11 AT AT99942074T patent/ATE414536T1/de active
- 1999-08-11 IL IL14134999A patent/IL141349A0/xx unknown
- 1999-08-11 CN CN200910151382A patent/CN101695574A/zh active Pending
- 1999-08-11 KR KR1020097001690A patent/KR101023367B1/ko not_active Ceased
- 1999-08-11 CN CNB2005100626872A patent/CN100409898C/zh not_active Ceased
- 1999-08-11 MX MXPA01001530A patent/MXPA01001530A/es not_active Application Discontinuation
- 1999-08-11 PL PL99346046A patent/PL195870B1/pl unknown
- 1999-08-11 EP EP08005897A patent/EP1946775A3/fr not_active Withdrawn
2000
- 2000-01-29 TW TW099139586A patent/TWI355941B/zh not_active IP Right Cessation
- 2000-01-29 TW TW097121912A patent/TWI343817B/zh not_active IP Right Cessation
- 2000-01-29 TW TW094114004A patent/TWI322014B/zh not_active IP Right Cessation
- 2000-01-29 TW TW088113738A patent/TWI242444B/zh not_active IP Right Cessation
2001
- 2001-02-09 NO NO20010699A patent/NO332893B3/no not_active IP Right Cessation
- 2001-02-09 IL IL141349A patent/IL141349A/en not_active IP Right Cessation
- 2001-02-09 ZA ZA200101157A patent/ZA200101157B/en unknown
2002
- 2002-07-17 US US10/196,732 patent/US20030026804A1/en not_active Abandoned
2003
- 2003-05-19 US US10/440,186 patent/US20030206903A1/en not_active Abandoned
2004
- 2004-02-27 AU AU2004200806A patent/AU2004200806A1/en not_active Abandoned
2007
- 2007-08-18 US US11/840,956 patent/US8329172B2/en not_active Expired - Fee Related
2008
- 2008-08-15 AU AU2008207357A patent/AU2008207357C1/en not_active Expired
2009
- 2009-02-02 CY CY20091100117T patent/CY1108906T1/el unknown
- 2009-05-14 JP JP2009117445A patent/JP2009173686A/ja active Pending
2010
- 2010-08-02 IL IL207358A patent/IL207358A/en not_active IP Right Cessation
- 2010-08-20 JP JP2010185374A patent/JP2010265318A/ja not_active Withdrawn
2011
- 2011-09-08 NO NO20111217A patent/NO20111217A1/no not_active Application Discontinuation
2012
- 2012-03-15 IL IL218665A patent/IL218665A0/en unknown
- 2012-06-15 US US13/524,800 patent/US20120251534A1/en not_active Abandoned
- 2012-06-15 US US13/524,896 patent/US9296821B2/en not_active Expired - Fee Related
- 2012-06-15 US US13/524,837 patent/US20120251535A1/en not_active Abandoned
- 2012-06-15 US US13/524,858 patent/US20120258101A1/en not_active Abandoned
- 2012-09-07 CY CY20121100809T patent/CY1113600T1/el unknown
2013
- 2013-04-23 US US13/868,753 patent/US20130273039A1/en not_active Abandoned
- 2013-08-13 JP JP2013168046A patent/JP2013227352A/ja active Pending
- 2013-11-01 US US14/070,256 patent/US20140056887A1/en not_active Abandoned
2015
- 2015-02-23 JP JP2015032737A patent/JP6241794B2/ja not_active Expired - Lifetime
- 2015-03-11 US US14/645,219 patent/US20150183882A1/en not_active Abandoned
2016
- 2016-08-01 US US15/225,594 patent/US10113000B2/en not_active Expired - Fee Related
- 2016-10-25 US US15/334,235 patent/US20170037140A1/en not_active Abandoned
2017
- 2017-05-02 JP JP2017091949A patent/JP6226216B2/ja not_active Expired - Lifetime
- 2017-09-19 JP JP2017178950A patent/JP2017214435A/ja active Pending
- 2017-10-03 JP JP2017193157A patent/JP6253842B2/ja not_active Expired - Lifetime
2018
- 2018-12-13 JP JP2018233050A patent/JP2019065023A/ja active Pending

Also Published As

Publication number	Publication date
KR101023367B1 (ko)	2011-03-18
CA2340091C (fr)	2013-02-05
NO332893B3 (no)	2017-09-18
NZ573838A (en)	2011-01-28
US20150183882A1 (en)	2015-07-02
CY1113600T1 (el)	2016-06-22
KR20090115895A (ko)	2009-11-09
TWI322014B (en)	2010-03-21
CN1320044A (zh)	2001-10-31
US20120251535A1 (en)	2012-10-04
US20030206903A1 (en)	2003-11-06
US9296821B2 (en)	2016-03-29
DK1974747T3 (da)	2012-09-17
JP2017128615A (ja)	2017-07-27
EP1112084A1 (fr)	2001-07-04
NO20111217A1 (no)	2011-09-08
US20130273039A1 (en)	2013-10-17
EP2275136A1 (fr)	2011-01-19
IL141349A (en)	2012-06-28
US20160333106A1 (en)	2016-11-17
AU2008207357C1 (en)	2017-05-04
EP1946775A2 (fr)	2008-07-23
CZ303898B6 (cs)	2013-06-19
HK1083449A1 (zh)	2006-07-07
HK1041221A1 (zh)	2002-07-05
US20120258102A1 (en)	2012-10-11
EP1112084B1 (fr)	2008-11-19
KR20110022097A (ko)	2011-03-04
JP2017222727A (ja)	2017-12-21
JP2017214435A (ja)	2017-12-07
MY136203A (en)	2008-08-29
EP1112084B2 (fr)	2012-04-25
EP1974747B1 (fr)	2012-06-27
NO332893B1 (no)	2013-01-28
CY1108906T1 (el)	2014-07-02
CN101695574A (zh)	2010-04-21
PT1974747E (pt)	2012-09-05
JP6241794B2 (ja)	2017-12-06
HU228180B1 (hu)	2013-01-28
AU767965C (en)	2005-04-21
KR20010072388A (ko)	2001-07-31
DK1112084T4 (da)	2012-07-23
MXPA01001530A (es)	2002-04-24
JP2002522511A (ja)	2002-07-23
JP2010265318A (ja)	2010-11-25
ES2388893T3 (es)	2012-10-19
US20120258101A1 (en)	2012-10-11
HUP0103484A2 (hu)	2002-01-28
CN100531798C (zh)	2009-08-26
US20140056887A1 (en)	2014-02-27
JP2013227352A (ja)	2013-11-07
JP6253842B2 (ja)	2017-12-27
EP2260866A1 (fr)	2010-12-15
KR20090014243A (ko)	2009-02-06
CZ2001526A3 (cs)	2002-11-13
US8329172B2 (en)	2012-12-11
AU2008207357A1 (en)	2008-09-04
CN1689644A (zh)	2005-11-02
US20120251534A1 (en)	2012-10-04
TW200846021A (en)	2008-12-01
AU2004200806A1 (en)	2004-03-25
TWI343817B (en)	2011-06-21
EP1946775A3 (fr)	2008-08-06
ES2317702T5 (es)	2012-07-11
AU767965B2 (en)	2003-11-27
JP2009173686A (ja)	2009-08-06
KR101155957B1 (ko)	2012-06-15
NO20010699L (no)	2001-04-10
DK1112084T3 (da)	2009-03-16
HK1122511A1 (en)	2009-05-22
EA200100224A1 (ru)	2001-08-27
TW201106974A (en)	2011-03-01
US10113000B2 (en)	2018-10-30
EP1112084A4 (fr)	2002-10-16
CN1689645A (zh)	2005-11-02
KR101063278B1 (ko)	2011-09-07
US20030026804A1 (en)	2003-02-06
EP2263693A1 (fr)	2010-12-22
EP2990054A1 (fr)	2016-03-02
TW200526248A (en)	2005-08-16
PL346046A1 (en)	2002-01-14
TWI242444B (en)	2005-11-01
JP6226216B2 (ja)	2017-11-08
DE69939939D1 (de)	2009-01-02
ATE414536T1 (de)	2008-12-15
AU2008207357B2 (en)	2011-07-14
CN100409898C (zh)	2008-08-13
CA2340091A1 (fr)	2000-02-24
WO2000009160A1 (fr)	2000-02-24
US20170037140A1 (en)	2017-02-09
IL141349A0 (en)	2002-03-10
ES2317702T3 (es)	2009-04-16
IL207358A (en)	2017-09-28
JP2015098486A (ja)	2015-05-28
US20080038261A1 (en)	2008-02-14
JP2019065023A (ja)	2019-04-25
IL218665A0 (en)	2012-05-31
PL195870B1 (pl)	2007-11-30
AU5553199A (en)	2000-03-06
NZ528199A (en)	2005-06-24
TWI355941B (en)	2012-01-11
HK1083444A1 (en)	2006-07-07
KR20080038453A (ko)	2008-05-06
EP1974747A1 (fr)	2008-10-01
EA004107B1 (ru)	2003-12-25
IL207358A0 (en)	2011-08-01
NO20010699D0 (no)	2001-02-09
US6455043B1 (en)	2002-09-24
BR9913645A (pt)	2001-09-25
CN1689646A (zh)	2005-11-02
PT1112084E (pt)	2009-02-20

Publication	Publication Date	Title
ZA200101157B (en)	2002-07-10	Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody.
HK1083449B (en)	2010-06-11	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
HK1083444B (en)	2009-05-08	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
HK1143322A (en)	2010-12-31	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
HK1151239A (en)	2012-01-27	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
HK1151247A (en)	2012-01-27	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
NZ585860A (en)	2011-12-22	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody